ISRCTN13470572已完成未知
tility of biomarkers for ovarian cancer risk assessment in primary care: a pilot study
niversity of Manchester0 个研究点目标入组 1,375 人开始时间: 2018年6月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1,375
研究概览
简要总结
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35565253/ (added 04/07/2022) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34036134/ (added 31/08/2022)
研究设计
- 研究类型
- Observational
入排标准
- 性别
- Female
入选标准
- •1. Women undergoing GP requested CA125 testing where the sample is processed by MFT
- •2. Aged over 18
- •1. Women who underwent initial CA125 and HE4 testing in phase 1 who are subsequently referred for further tests or treatment
- •2. Ability to provide informed consent
- •3. Aged over 18 years
排除标准
- •Inability to provide informed consent
研究者
相似试验
进行中（未招募）
不适用
Predicting risk of ovarian malignancy improved screening and early detection feasibility studyPrevention of ovarian cancerMalignant neoplasm of ovaryCancerISRCTN54246466Queen Mary University of London140
已完成
不适用
New Biomarkers Evaluating Ovarian CancerAdnexal MassNCT01466049Fujirebio Diagnostics, Inc.280
招募中
不适用
A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian MassOvarian NeoplasmsNCT06566716Cleo Diagnostics Ltd1,000
招募中
不适用
Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian CancerEpithelial Ovarian CancerNCT05874115Centro di Riferimento Oncologico - Aviano75
已完成
不适用
Ovarian Cancer Risk Estimation in Patients With Pelvic MassAdnexal MassOvarian CancerNCT00987649Fujirebio Diagnostics, Inc.512